Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, opened for enrollment in early May. These sites are continuing to actively screen for patients.
Expanded Access is a program that allows patients to receive an investigational treatment not yet approved by the United States Food and Drug Administration (FDA) outside of a clinical trial. The program is for patients with serious or life-threatening conditions who do not have promising treatment options and are unable to participate in ongoing clinical trials.
